Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Musa Tariq sold 116 shares of Guardant Health stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $149.56, for a total value of $17,348.96. Following the completion of the transaction, the director directly owned 11,717 shares of the company's stock, valued at approximately $1,752,394.52. This represents a 0.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Musa Tariq also recently made the following trade(s):
- On Friday, October 16th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $165.88, for a total value of $19,242.08.
- On Wednesday, September 16th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $175.00, for a total value of $20,300.00.
Guardant Health Trading Down 0.5%
NASDAQ:GH traded down $0.75 during mid-day trading on Tuesday, hitting $143.28. The stock had a trading volume of 1,960,154 shares, compared to its average volume of 2,217,595. The stock has a 50-day simple moving average of $168.29 and a two-hundred day simple moving average of $133.16. The company has a market capitalization of $19.38 billion, a PE ratio of -38.93 and a beta of 1.67. Guardant Health, Inc. has a twelve month low of $74.55 and a twelve month high of $191.05.
Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.75) by $0.46. The company had revenue of $360.98 million for the quarter, compared to analyst estimates of $350.72 million. During the same period in the previous year, the business posted ($0.74) EPS. The firm's revenue for the quarter was up 36.1% compared to the same quarter last year. Sell-side analysts predict that Guardant Health, Inc. will post -3.08 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research analysts have weighed in on GH shares. Barclays upped their target price on shares of Guardant Health from $200.00 to $220.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 7th. Rothschild & Co Redburn started coverage on Guardant Health in a research note on Tuesday, September 8th. They set a "buy" rating and a $203.00 price target on the stock. Stifel Nicolaus upped their price target on Guardant Health from $130.00 to $180.00 and gave the stock a "buy" rating in a report on Friday, July 31st. Morgan Stanley raised their price objective on Guardant Health from $185.00 to $200.00 and gave the company an "overweight" rating in a research note on Monday, October 12th. Finally, UBS Group lifted their price objective on Guardant Health from $175.00 to $225.00 and gave the stock a "buy" rating in a report on Wednesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $190.88.
View Our Latest Analysis on Guardant Health
Institutional Investors Weigh In On Guardant Health
A number of large investors have recently bought and sold shares of GH. The Manufacturers Life Insurance Company acquired a new position in shares of Guardant Health in the 2nd quarter valued at about $208,592,000. William Blair Investment Management LLC purchased a new stake in shares of Guardant Health during the 2nd quarter worth about $196,737,000. PointState Capital LP purchased a new stake in shares of Guardant Health during the 3rd quarter worth about $176,851,000. Healthcare of Ontario Pension Plan Trust Fund grew its holdings in shares of Guardant Health by 443,025.0% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 709,000 shares of the company's stock worth $126,457,000 after purchasing an additional 708,840 shares during the period. Finally, Orbimed Advisors LLC acquired a new stake in Guardant Health during the 1st quarter worth approximately $40,199,000. Institutional investors and hedge funds own 92.60% of the company's stock.
Guardant Health Company Profile
(
Get Free Report)
Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Guardant Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.
While Guardant Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.